PURPOSE: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) measured the early vascular changes after administration of TRA-8, bevacizumab, or TRA-8 combined with bevacizumab in breast tumor xenografts. PROCEDURES: Groups 1-4 of nude mice bearing human breast carcinoma were injected with phosphate-buffered saline, TRA-8, bevacizumab, and TRA-8 + bevacizumab on day 0, respectively. DCE-MRI was performed on days 0, 1, 2, and 3, and thereafter tumors were collected for terminal deoxynucleotidyl transferase-mediated dUT nick end labeling and CD31 staining. RESULTS: DCE-MRI measured a significant K (trans) change within 3 days after TRA-8 therapy that correlated with tumor growth arrest, which was not shown with statistical significance by histopathology at these early time points posttreatment. The K (trans) changes followed quadratic polynomial curves. CONCLUSION: DCE-MRI detected significantly lower K (trans) levels in breast tumor xenografts following TRA-8 monotherapy or combined therapy with bevacizumab.
PURPOSE: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) measured the early vascular changes after administration of TRA-8, bevacizumab, or TRA-8 combined with bevacizumab in breast tumor xenografts. PROCEDURES: Groups 1-4 of nude mice bearing humanbreast carcinoma were injected with phosphate-buffered saline, TRA-8, bevacizumab, and TRA-8 + bevacizumab on day 0, respectively. DCE-MRI was performed on days 0, 1, 2, and 3, and thereafter tumors were collected for terminal deoxynucleotidyl transferase-mediated dUT nick end labeling and CD31 staining. RESULTS:DCE-MRI measured a significant K (trans) change within 3 days after TRA-8 therapy that correlated with tumor growth arrest, which was not shown with statistical significance by histopathology at these early time points posttreatment. The K (trans) changes followed quadratic polynomial curves. CONCLUSION:DCE-MRI detected significantly lower K (trans) levels in breast tumor xenografts following TRA-8 monotherapy or combined therapy with bevacizumab.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Thomas E Yankeelov; Jeffrey J Luci; Martin Lepage; Rui Li; Laura Debusk; P Charles Lin; Ronald R Price; John C Gore Journal: Magn Reson Imaging Date: 2005-05 Impact factor: 2.546
Authors: Thomas E Yankeelov; Greg O Cron; Christina L Addison; Julia C Wallace; Ruth C Wilkins; Bruce A Pappas; Giles E Santyr; John C Gore Journal: Magn Reson Med Date: 2007-02 Impact factor: 4.668
Authors: J G Emery; P McDonnell; M B Burke; K C Deen; S Lyn; C Silverman; E Dul; E R Appelbaum; C Eichman; R DiPrinzio; R A Dodds; I E James; M Rosenberg; J C Lee; P R Young Journal: J Biol Chem Date: 1998-06-05 Impact factor: 5.157
Authors: J P Sheridan; S A Marsters; R M Pitti; A Gurney; M Skubatch; D Baldwin; L Ramakrishnan; C L Gray; K Baker; W I Wood; A D Goddard; P Godowski; A Ashkenazi Journal: Science Date: 1997-08-08 Impact factor: 47.728
Authors: Kenneth J Niermann; Arthur C Fleischer; Jessica Huamani; Thomas E Yankeelov; Dong W Kim; Wendy D Wilson; Dennis E Hallahan Journal: J Ultrasound Med Date: 2007-06 Impact factor: 2.153
Authors: P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff Journal: J Magn Reson Imaging Date: 1999-09 Impact factor: 4.813
Authors: Bonnie L Hylander; Rose Pitoniak; Remedios B Penetrante; John F Gibbs; Dilek Oktay; Jinrong Cheng; Elizabeth A Repasky Journal: J Transl Med Date: 2005-05-19 Impact factor: 5.531
Authors: Hyunki Kim; Guihua Zhai; Zhiyong Liu; Sharon Samuel; Nemil Shah; Emily E Helman; Joseph A Knowles; Cecil R Stockard; Naomi S Fineberg; William E Grizzle; Tong Zhou; Kurt R Zinn; Eben L Rosenthal Journal: Anticancer Drugs Date: 2011-10 Impact factor: 2.248
Authors: Hyunki Kim; Guihua Zhai; Sharon L Samuel; Christopher J Rigell; Heidi R Umphrey; Samir Rana; Cecil R Stockard; Naomi S Fineberg; Kurt R Zinn Journal: Mol Cancer Ther Date: 2011-12-27 Impact factor: 6.261
Authors: Hyunki Kim; Christopher J Rigell; Guihua Zhai; S Kyle Lee; Sharon L Samuel; Amber Martin; Heidi R Umphrey; Cecil R Stockard; T Mark Beasley; Donald J Buchsbaum; Long Shan Li; David A Boothman; Kurt R Zinn Journal: Mol Imaging Biol Date: 2013-07-09 Impact factor: 3.488
Authors: Samuel R Barnes; Thomas S C Ng; Axel Montagne; Meng Law; Berislav V Zlokovic; Russell E Jacobs Journal: Magn Reson Med Date: 2015-06-16 Impact factor: 4.668
Authors: Ergys Subashi; Everett J Moding; Gary P Cofer; James R MacFall; David G Kirsch; Yi Qi; G Allan Johnson Journal: Med Phys Date: 2013-02 Impact factor: 4.071